Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18777896 | USE OF ITACONATE AND ITS DERIVATIVES/ANALOGUES TO INDUCE HAIR GROWTH | July 2024 | January 2025 | Allow | 6 | 1 | 1 | Yes | No |
| 18680463 | THERAPEUTIC COMPOSITION, METHODS, AND USES FOR THE CONTROL OF SEIZURES | May 2024 | December 2025 | Abandon | 18 | 2 | 1 | No | No |
| 18664847 | FORMULATIONS FOR THE TREATMENT OF OCULAR SURFACE DISEASES AND RELATED METHODS | May 2024 | January 2026 | Abandon | 20 | 1 | 1 | No | No |
| 18661516 | USE OF ADAMANTANE COMPOSITIONS AND METHODS OF REDUCING FIBROTIC TISSUE | May 2024 | April 2025 | Allow | 11 | 1 | 1 | No | No |
| 18646306 | ETHYL-2-{[(2,4-DICHLOROBENZOYL)CARBAMOTHIOYL]AMINO}-4,5,6,7- TETRAHYDRO-1-BENZOTHIOPHENE-3-CARBOXYLATE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | April 2024 | October 2024 | Allow | 6 | 1 | 0 | No | No |
| 18646222 | ETHYL-2-{[(2,4-DICHLOROBENZOYL)CARBAMOTHIOYL]AMINO}-4,5,6,7- TETRAHYDRO-1-BENZOTHIOPHENE-3-CARBOXYLATE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | April 2024 | September 2024 | Allow | 5 | 0 | 1 | No | No |
| 18643253 | VASOCONSTRICTION COMPOSITIONS AND METHODS OF USE | April 2024 | September 2025 | Allow | 16 | 2 | 1 | No | No |
| 18614442 | PI3K-ALPHA INHIBITOR AND MTOR INHIBITOR COMBINATIONS FOR CANCER TREATMENT | March 2024 | November 2025 | Abandon | 19 | 3 | 1 | No | No |
| 18603789 | COMPOSITIONS AND METHODS FOR TREATING AND/OR PREVENTING CARDIOVASCULAR DISEASE | March 2024 | July 2025 | Abandon | 16 | 0 | 1 | No | No |
| 18602435 | PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | March 2024 | December 2025 | Allow | 21 | 1 | 1 | No | No |
| 18590387 | SALTS AND ESTERS OF APX3330 AND THERAPEUTIC USES THEREOF | February 2024 | January 2025 | Allow | 11 | 1 | 2 | No | No |
| 18439517 | SELECTIVE HYPOTHALAMUS PERMEABLE HDAC6 INHIBITORS FOR TREATMENT OF LEPTIN-RESISTANT OBESITY | February 2024 | May 2025 | Abandon | 15 | 2 | 1 | No | No |
| 18437098 | APPLICATIONS FOR NICARDIPINE IN PREPARING ANTI-LUNG CANCER PRODUCTS | February 2024 | June 2025 | Allow | 16 | 1 | 1 | No | No |
| 18436341 | NEURONAL NICOTINIC ACETYLCHOLINE RECEPTOR PARTIAL AGONISTS AS THERAPEUTICS FOR CHRONIC TINNITUS | February 2024 | July 2025 | Abandon | 18 | 1 | 1 | No | No |
| 18426080 | 3-(4,5-BIS(4-BROMOPHENYL)-2-(4-CHLOROPHENYL)-1H-IMIDAZOL-1-YL)PROPANOIC ACID AS AN ANTIMICROBIAL COMPOUND | January 2024 | March 2024 | Allow | 2 | 0 | 0 | No | No |
| 18426095 | 3-(4,5-BIS(4-BROMOPHENYL)-2-(4-CHLOROPHENYL)-1H-IMIDAZOL-1-YL)PROPANOIC ACID AS AN ANTIMICROBIAL COMPOUND | January 2024 | August 2024 | Allow | 7 | 1 | 0 | No | No |
| 18397458 | PHARMACEUTICAL COMPOSITION COMPRISING AN ANDROGEN RECEPTOR INHIBITOR | December 2023 | November 2025 | Allow | 23 | 2 | 1 | No | No |
| 18533345 | 3-(4,5-DIPHENYL-2-(PYRIDIN-3-YL)-1H-IMIDAZOL-1-YL)-N,N-DIMETHYLPOPAN-1-AMINE AS AN ANTIMICROBIAL COMPOUND | December 2023 | April 2024 | Allow | 4 | 0 | 1 | No | No |
| 18533359 | 3-(4,5-DIPHENYL-2-(PYRIDIN-3-YL)-1H-IMIDAZOL-1-YL)-N,N-DIMETHYLPOPAN-1-AMINE AS AN ANTIMICROBIAL COMPOUND | December 2023 | March 2024 | Allow | 3 | 0 | 0 | No | No |
| 18531121 | Compounds and Dosage Regimen for Use in the Prevention or Treatment of Chronic Inflammatory and/or Autoimmune Diseases | December 2023 | January 2026 | Allow | 26 | 1 | 1 | No | No |
| 18516541 | Composition for Preventing or Treating Obesity or Lipid-Related Metabolic Disorders | November 2023 | July 2025 | Abandon | 20 | 1 | 1 | No | No |
| 18512564 | HBV INHIBITOR AND ITS USE | November 2023 | March 2025 | Allow | 16 | 2 | 1 | No | No |
| 18384719 | PHARMACEUTICAL COMPOSITIONS, COMPRISING A COMBINATION OF SELECT CARRIERS AND FLAVONOIDS AS ANTIPATHOGENS | October 2023 | November 2025 | Abandon | 24 | 1 | 1 | Yes | No |
| 18384602 | ETHYL-2-{[(2,4-DICHLOROBENZOYL)CARBAMOTHIOYL]AMINO}-4,5,6,7- TETRAHYDRO-1-BENZOTHIOPHENE-3-CARBOXYLATE AS AN ECOFRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | October 2023 | April 2024 | Allow | 5 | 0 | 1 | No | No |
| 18382855 | 3-(4,5-BIS(4-BROMOPHENYL)-2-(4-CHLOROPHENYL)-1H-IMIDAZOL-1-YL)PROPANOIC ACID AS AN ANTIMICROBIAL COMPOUND | October 2023 | March 2024 | Allow | 5 | 0 | 1 | No | No |
| 18380680 | TERPENE-ENRICHED CANNABINOID COMPOSITION | October 2023 | October 2025 | Abandon | 24 | 2 | 1 | No | No |
| 18479357 | GLUTAMINE ANTAGONISTS FOR THE TREATMENT OF COGNITIVE DEFICITS AND PSYCHIATRIC DISORDERS | October 2023 | October 2025 | Abandon | 24 | 1 | 1 | No | No |
| 18373505 | Heterocyclic Carboxylate Compounds as Glycolate Oxidase Inhibitors | September 2023 | September 2024 | Allow | 11 | 0 | 1 | No | No |
| 18467366 | Steroidal Compositions | September 2023 | March 2026 | Abandon | 30 | 1 | 1 | No | No |
| 18367582 | COMPOSITIONS AGAINST CANDIDA INFECTIONS | September 2023 | April 2025 | Allow | 19 | 1 | 1 | No | No |
| 18367713 | GLYCERYL AND GLYCOL ACID COMPOUNDS | September 2023 | January 2025 | Allow | 17 | 2 | 1 | No | No |
| 18549377 | Fluorinated Empathogens | September 2023 | August 2024 | Allow | 11 | 0 | 1 | No | No |
| 18462920 | ARYL-SUBSTITUTED ACETAMIDE AND PYRROLIDIN-2-ONE DERIVATIVES AND THEIR USE FOR THE TREATMENT OF SEIZURES | September 2023 | March 2025 | Allow | 18 | 1 | 1 | No | No |
| 18242194 | 3-(4,5-DIPHENYL-2-(PYRIDIN-3-YL)-1H-IMIDAZOL-1-YL)-N,N-DIMETHYLPOPAN-1-AMINE AS AN ANTIMICROBIAL COMPOUND | September 2023 | February 2024 | Allow | 5 | 0 | 1 | No | No |
| 18453937 | METHODS OF TREATING DISEASE WITH DICHLORPHENAMIDE | August 2023 | April 2025 | Abandon | 19 | 3 | 1 | Yes | Yes |
| 18447130 | INHIBITORS OF ALPHA-AMINO-BETA-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE | August 2023 | September 2024 | Allow | 13 | 3 | 1 | No | No |
| 18364621 | SUBSTITUTED BENZOTHIOPHENE ANALOGS AS SELECTIVE ESTROGEN RECEPTOR DEGRADERS | August 2023 | March 2025 | Allow | 20 | 1 | 1 | No | No |
| 18219765 | INHIBITOR FOR RETINOCHOROIDAL DISORDERS | July 2023 | March 2025 | Allow | 20 | 1 | 0 | No | No |
| 18217002 | Quinolone Derivatives as Fibroblast Growth Factor Receptor Inhibitors | June 2023 | July 2024 | Allow | 13 | 0 | 1 | No | No |
| 18344406 | NOVEL USES | June 2023 | December 2025 | Allow | 30 | 3 | 1 | No | No |
| 18341613 | COMPOSITIONS AND METHODS OF TREATING RETINAL DISEASE | June 2023 | July 2025 | Allow | 25 | 1 | 0 | No | No |
| 18213416 | COMPOSITIONS AND METHODS OF USE OF GAMMA-KETOALDHEYDE SCAVENGERS FOR TREATING, PREVENTING OR IMPROVING FIBROSIS OF THE LIVER | June 2023 | January 2026 | Allow | 31 | 2 | 1 | No | No |
| 18324598 | SELECTIVE HYPOTHALAMUS PERMEABLE HDAC6 INHIBITORS FOR TREATMENT OF LEPTIN-RESISTANT OBESITY | May 2023 | March 2025 | Abandon | 21 | 3 | 1 | Yes | No |
| 18315353 | VASOCONSTRICTION COMPOSITIONS AND METHODS OF USE | May 2023 | April 2025 | Allow | 23 | 1 | 1 | No | No |
| 18312790 | METHODS AND RELATED COMPOSITIONS FOR REDUCTION OF FAT AND SKIN TIGHTENING | May 2023 | June 2025 | Abandon | 25 | 1 | 1 | No | No |
| 18142909 | PHARMACEUTICAL COMPOSITIONS OF IBRUTINIB | May 2023 | January 2025 | Abandon | 20 | 1 | 1 | No | No |
| 18308961 | USE OF CYP26-RESISTANT RAR ALPHA SELECTIVE AGONISTS IN THE TREATMENT OF CANCER | April 2023 | February 2025 | Abandon | 21 | 1 | 1 | No | No |
| 18134609 | THERAPEUTIC AGENT FOR TREATING BRADYARRHYTHMIA | April 2023 | October 2024 | Allow | 18 | 1 | 1 | No | No |
| 18248097 | USE OF PARABULIN FOR TARGETING PROTOZOAN TUBULIN FOR THE INHIBITION OF PROTOZOAN REPLICATION | April 2023 | February 2026 | Allow | 34 | 1 | 0 | No | No |
| 18125002 | METHODS AND COMPOSITIONS TO SUPPORT THE GROWTH OR MAINTENANCE OF OXYGEN-SENSITIVE BACTERIA IN THE GASTROINTESTINAL TRACT | March 2023 | January 2025 | Abandon | 22 | 1 | 1 | No | No |
| 18122664 | Antibacterial Treatments Using Cannabinoids | March 2023 | May 2025 | Abandon | 26 | 1 | 1 | No | No |
| 18044697 | USE OF N-(3-(4-(3-(DIISOBUTYLAMINO)PROPYL)PIPERAZIN-1-YL)PROPYL)-1H-BENZO[D]IMIDAZOL-2-AMINE SULPHATE SALTS AND SOLVATES THEREOF FOR THE TREATMENT OF MOTOR NEURON DISEASES AND NEUROMUSCULAR JUNCTION DISORDERS | March 2023 | January 2026 | Allow | 34 | 0 | 1 | No | No |
| 18174091 | METHODS OF TREATING HYPERTRIGLYCERIDEMIA | February 2023 | March 2025 | Abandon | 24 | 1 | 1 | No | No |
| 18106925 | TREATMENT OF COVID-19 ASSOCIATED COGNITIVE DYSFUNCTION BY NUTRACEUTICAL PREPARATIONS | February 2023 | October 2024 | Abandon | 20 | 1 | 2 | No | No |
| 18164587 | USE OF PRIDOPIDINE FOR TREATING FUNCTIONAL DECLINE | February 2023 | December 2025 | Abandon | 34 | 4 | 0 | No | No |
| 18103404 | VASOCONSTRICTION COMPOSITIONS AND METHODS OF USE | January 2023 | July 2023 | Allow | 6 | 2 | 0 | No | No |
| 18158284 | PHARMACEUTICAL COMPOSITION FOR TREATING ACUTE AND CHRONIC PAIN, CONTAINING POLMACOXIB AND TRAMADOL | January 2023 | March 2024 | Abandon | 14 | 1 | 1 | No | No |
| 18157216 | COMBINATION TREATMENT OF LIVER DISORDERS | January 2023 | July 2024 | Abandon | 18 | 0 | 1 | No | No |
| 18099200 | PROPHYLACTIC OR THERAPEUTIC AGENT FOR HYPOXIC INJURY, ISCHAEMIA-REPERFUSION INJURY AND INFLAMMATION, CELL PROTECTION AGENT FOR TRANSPLANTATION, AND BIO-PRESERVATION AGENT | January 2023 | April 2024 | Allow | 15 | 1 | 1 | No | No |
| 18095429 | Development of Potential Antidotes for Arsenicals | January 2023 | October 2024 | Allow | 21 | 2 | 1 | No | No |
| 18151232 | DRUG COMBINATION FOR TREATING OBESITY | January 2023 | February 2026 | Allow | 37 | 5 | 1 | Yes | No |
| 18092723 | Spirolactone Compounds | January 2023 | April 2024 | Allow | 16 | 1 | 1 | No | No |
| 18085119 | USE OF RIP1 INHIBITOR OR MLKL INHIBITOR FOR TREATING OR PREVENTING HEREDITARY RETINAL DYSTROPHY | December 2022 | September 2024 | Abandon | 21 | 1 | 1 | No | No |
| 18068682 | PTGDR-1 AND/OR PTGDR-2 ANTAGONISTS FOR PREVENTING AND/OR TREATING SYSTEMIC LUPUS ERYTHEMATOSUS | December 2022 | May 2024 | Abandon | 16 | 0 | 1 | No | No |
| 18060934 | PD-1/PD-L1 INHIBITORS | December 2022 | February 2025 | Allow | 26 | 2 | 1 | No | No |
| 17993003 | Aminothiolester compounds or pharmaceutically acceptable salts thereof, for use for the treatment of cancer | November 2022 | August 2024 | Abandon | 21 | 2 | 1 | No | No |
| 17992162 | COMPOUNDS AND DOSAGE REGIMEN FOR USE IN THE PREVENTION OR TREATMENT OF CHRONIC INFLAMMATORY AND/OR AUTOIMMUNE DISEASES | November 2022 | November 2023 | Allow | 12 | 0 | 1 | Yes | No |
| 17991581 | COMPOSITION COMPRISING A METAL ASCORBO-CAMPHORATE COMPOUND AND METHOD FOR PREVENTION AND/OR TREATMENT OF PAPILLOMAVIRUS INFECTIONS | November 2022 | March 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17989705 | ANTIBACTERIAL AND BIOFILM FORMATION-INHIBITING COMPOSITION CONTAINING MYRISTOLEIC ACID AS ACTIVE INGREDIENT | November 2022 | January 2026 | Allow | 49 | 1 | 1 | No | No |
| 17983844 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | November 2022 | February 2025 | Allow | 27 | 3 | 1 | No | No |
| 17923183 | LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES | November 2022 | September 2025 | Allow | 35 | 0 | 1 | No | No |
| 18045595 | Inhibitors of GPR174 and Uses Thereof | October 2022 | May 2024 | Abandon | 19 | 0 | 1 | No | No |
| 17937067 | NEUROKININ ANTAGONISTS AND USES THEREOF | September 2022 | May 2024 | Allow | 19 | 2 | 1 | No | No |
| 17916448 | PYRANO[4,3-B]INDOLE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | September 2022 | July 2025 | Allow | 34 | 0 | 1 | No | No |
| 17912687 | Bioactive Supplement | September 2022 | February 2026 | Allow | 41 | 1 | 0 | No | No |
| 17906472 | THERAPEUTIC TREATMENT OF CHROMATINOPATHIES | September 2022 | January 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17911230 | NOVEL NANO-FORMULATION OF CANNABIDIOL (CBD) AND OTHER CANNABINOIDS FOR TREATMENT OF OCULAR DISORDERS | September 2022 | January 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17930798 | PROPOFOL PRODRUG METHODS AND COMPOSITIONS | September 2022 | September 2023 | Abandon | 12 | 0 | 1 | No | No |
| 17799637 | DIHYDRONAPHTHYRIDINONE COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | August 2022 | February 2026 | Allow | 42 | 1 | 1 | No | No |
| 17875871 | FORMULATIONS FOR THE TREATMENT OF OCULAR SURFACE DISEASES AND RELATED METHODS | July 2022 | July 2024 | Abandon | 24 | 2 | 0 | No | No |
| 17866795 | TREATMENT OF TACHYCARDIA | July 2022 | May 2023 | Abandon | 9 | 0 | 0 | No | No |
| 17812994 | METHODS FOR TREATING HYPERTROPHIC CARDIOMYOPATHY | July 2022 | March 2025 | Abandon | 32 | 3 | 1 | No | No |
| 17864319 | TREATMENT OF A DISEASE OF THE GASTROINTESTINAL TRACT WITH A TLR MODULATOR | July 2022 | December 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17850806 | METHODS OF TREATING SOLID TUMORS USING NANOPARTICLE MTOR INHIBITOR COMBINATION THERAPY | June 2022 | June 2025 | Abandon | 35 | 1 | 1 | No | No |
| 17850014 | CO-CRYSTALS OF NURR1-LBD IN COMPLEX WITH A CYCLOPENTENONE PROSTAGLANDIN AND MODULATORS OF NURR1 | June 2022 | March 2024 | Allow | 20 | 1 | 2 | No | No |
| 17784594 | THERAPEUTIC COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF DIASTOLIC DYSFUNCTION | June 2022 | December 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17783531 | SMALL MOLECULE INHIBITORS OF VOLTAGE-GATED SODIUM CHANNEL 1.7 AND METHODS OF USING SAME | June 2022 | September 2025 | Allow | 40 | 1 | 1 | No | No |
| 17834667 | COMBINATION THERAPIES TARGETING MITOCHONDRIAL BIOGENESIS FOR CANCER THERAPY | June 2022 | January 2024 | Abandon | 20 | 1 | 0 | No | No |
| 17826389 | METHOD FOR PREVENTING OCCURRENCE OF CARDIOVASCULAR EVENT IN MULTIPLE RISK PATIENT | May 2022 | January 2024 | Abandon | 19 | 1 | 0 | No | No |
| 17750888 | USE OF AR INHIBITOR AND/OR HIF-1 A A INHIBITOR IN PREPARATION OF MEDICAMENT | May 2022 | November 2023 | Abandon | 18 | 2 | 1 | No | No |
| 17662863 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY | May 2022 | September 2024 | Abandon | 28 | 1 | 1 | No | No |
| 17776001 | AN INHIBITOR OF AN IRON-CONTAINING HYDROGENASE OF A METHANOGENIC ARCHAEON FOR USE IN THE TREATMENT OR PREVENTION OF A PARKINSONIAN CONDITION | May 2022 | December 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17775375 | METHODS OF TREATMENT WITH MYOSIN MODULATOR | May 2022 | March 2026 | Abandon | 46 | 1 | 1 | No | No |
| 17734132 | TERPENE-ENRICHED CANNABINOID COMPOSITION | May 2022 | November 2025 | Abandon | 42 | 5 | 1 | No | No |
| 17772882 | USE OF ITACONATE AND ITS DERIVATIVES/ANALOGUES TO INDUCE HAIR GROWTH | April 2022 | September 2025 | Allow | 41 | 1 | 1 | No | No |
| 17755399 | Use of Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases | April 2022 | December 2025 | Allow | 43 | 1 | 1 | No | No |
| 17716082 | TERMITICIDE COMPOSITION AND METHODS FOR TREATING TERMITES | April 2022 | September 2025 | Allow | 41 | 4 | 2 | Yes | No |
| 17765802 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY | March 2022 | July 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17711014 | Micelle preparations of full-spectrum hemp oil | March 2022 | February 2024 | Allow | 22 | 2 | 3 | No | No |
| 17701160 | STABLE AQUEOUS CAPSAICIN INJECTABLE FORMULATIONS AND MEDICAL USES THEREOF | March 2022 | January 2024 | Allow | 22 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SZNAIDMAN, MARCOS L.
With a 26.0% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 12.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SZNAIDMAN, MARCOS L works in Art Unit 1628 and has examined 1,215 patent applications in our dataset. With an allowance rate of 38.7%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 36 months.
Examiner SZNAIDMAN, MARCOS L's allowance rate of 38.7% places them in the 7% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SZNAIDMAN, MARCOS L receive 2.44 office actions before reaching final disposition. This places the examiner in the 70% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by SZNAIDMAN, MARCOS L is 36 months. This places the examiner in the 34% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +21.1% benefit to allowance rate for applications examined by SZNAIDMAN, MARCOS L. This interview benefit is in the 65% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 13.6% of applications are subsequently allowed. This success rate is in the 9% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 21.0% of cases where such amendments are filed. This entry rate is in the 26% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 71.8% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 59% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 51.9% of appeals filed. This is in the 22% percentile among all examiners. Of these withdrawals, 61.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 49.7% are granted (fully or in part). This grant rate is in the 46% percentile among all examiners. Strategic Note: Petitions show below-average success regarding this examiner's actions. Ensure you have a strong procedural basis before filing.
Examiner's Amendments: This examiner makes examiner's amendments in 1.2% of allowed cases (in the 69% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 8.1% of allowed cases (in the 86% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.